During the past decade, MedStar Chesapeake CardioVascular Associates conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "MedStar Chesapeake CardioVascular Associates" are "Cardiovascular Disease" (2 trials), "Amyloid Cardiomyopathy" (1 trials), "Amyloidosis" (1 trials), "Cardiomyopathies" (1 trials) and "Heart Diseases" (1 trials). Many other conditions were trialed in "MedStar Chesapeake CardioVascular Associates" in a lesser frequency.

Most popular intervention types in "MedStar Chesapeake CardioVascular Associates" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Acoramidis (AG10)" (1 trials), "Placebo Oral Tablet" (1 trials) and "acoramidis" (1 trials). Other intervention names were less common.

The vast majority of trials in "MedStar Chesapeake CardioVascular Associates" are 4 trials for "All" genders.

Currently, there are NaN active trials in "MedStar Chesapeake CardioVascular Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were undefined completed trials in MedStar Chesapeake CardioVascular Associates, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in MedStar Chesapeake CardioVascular Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".